Cencora Updates Segment Reporting Following Strategic Business Review

Valentine's Day Sale - 70% OffUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialCencora ( (COR) ) just unveiled an announcement. Cencora, Inc. has revised how it presents historical financial information from its fiscal 2025 annual report to reflect a new segment structure adopted after a strategic review of its business. Effective with the first quarter of fiscal 2026, ended December 31, 2025, the company reorganized into U.S. Healthcare Solutions, International Healthcare Solutions and an “Other” category that houses businesses for which strategic alternatives are being explored. The company filed a Form 8-K, accompanied by updated disclosures, to realign prior segment results in its 2025 annual report with the new structure used in its fiscal 2026 first-quarter Form 10-Q filed on February 4, 2026. The filing is informational only, does not alter audited 2025 financial statements or introduce new events, and is intended to ensure that any filings incorporating the 2025 report now reflect the reclassified segment information for investors and other stakeholders. The most recent analyst rating on (COR) stock is a Buy with a $429.00 price target. To see the full list of analyst forecasts on Cencora stock, see the COR Stock Forecast page. Spark’s Take on COR Stock According to Spark, TipRanks’ AI Analyst, COR is a Neutral. The score is primarily supported by solid cash generation and upbeat management commentary with raised FY2026 guidance. It is held back by balance-sheet leverage and structurally thin margins, with additional pressure from weak near-term technicals and a high P/E with a modest dividend yield. To see Spark’s full report on COR stock, click here. More about Cencora Cencora, Inc. operates in the healthcare services and pharmaceutical distribution industry, providing healthcare solutions across U.S. and international markets. Its operations now center on two reportable segments, U.S. Healthcare Solutions and International Healthcare Solutions, while other non-core businesses are grouped in a separate “Other” category as the company explores strategic options for them. The U.S. Healthcare Solutions segment focuses on U.S. Human Health activities excluding legacy U.S. Consulting Services, and International Healthcare Solutions aggregates Alliance Healthcare, Innomar, World Courier and strategic components of Pharmalex. The remaining operations, including MWI Animal Health, Profarma, U.S. Consulting Services and other Pharmalex components, are treated as non-reportable businesses under review. Average Trading Volume: 1,400,240 Technical Sentiment Signal: Buy Current Market Cap: $69.89B